Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Design Therapeutics Inc.
Headquarters: Carlsbad, CA, United States of America
Website: http://www.designtx.com
Year Founded: 2017
Status: Public
Industry Sector: HealthTechnology
CEO: Pratik Shah, PhD, MBA
Number Of Employees: 54
Enterprise Value: $105,999,666
PE Ratio: -5.39
Exchange/Ticker 1: NASDAQ:DSGN
Exchange/Ticker 2: N/A
Latest Market Cap: $267,919,888
BioCentury | Sep 26, 2024
Management Tracks
Draghia-Akli, a veteran of J&J and Merck, joins Novavax as head of R&D
Plus: Septerna expands clinical team and an update from AAM
BioCentury | Aug 16, 2023
Regulation
Aug. 15 Quick Takes: April PDUFA for Carvykti in earlier stage MM
Plus: Nucleic acid company Impilo launches to treat solid tumors and updates from Galecto, Design, Arcellx, Amicus, Alaunos, Lidao
BioCentury | Sep 15, 2022
Finance
Sept. 14 Quick Takes: Apollomics going public via SPAC deal
Plus RayzeBio raises $160M in series D for radiopharmaceuticals, and updates from Point, Larimar, Worg and more
BioCentury | Feb 3, 2022
Management Tracks
New CMOs at Design, Mesoblast
Plus Loerop becomes CBO at Aclaris, updates from Clover, Kura, Fabric and more
BioCentury | Aug 24, 2021
Management Tracks
Brun leaves the board at Merck
Plus: Aristea, GT, Connect, Xenon and more
BioCentury | Mar 26, 2021
Finance
Valuations spiral into billions as trio of IPOs post big aftermarket gains: Data Byte
Design Therapeutics became the latest preclinical company to score a billion-dollar valuation as it went public ahead of Friday’s session, and its shares more than doubled in value during the
BioCentury | Jan 29, 2021
Finance
Jan. 28 Quick Takes: Sana aims high in latest IPO prospectus; plus short interest in biotech, and fundings for Curevac, Design, Ukko, Encodia and more
Gene and cell therapy company Sana Biotechnology Inc. proposed terms for an IPO on NASDAQ in which it hopes to sell 15 million shares at $20-$23. At the midpoint, the company would raise $322.5
BioCentury | Oct 20, 2020
Management Tracks
J&J promotes Kumar; plus moves at Krystal, Design, Centogene, Lyndra, Mereo and Neoleukin
Johnson & Johnson (NYSE:JNJ) has promoted Seema Kumar to global head of the Office of Innovation, Global Health and Scientific Engagement from VP of innovation, global health and policy
Items per page:
1 - 8 of 8